Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.

A positive trend for pCR was shown in EGFR overexpressed BC (58% vs 28%, p = 0.079), suggesting a potential benefit of anti-EGFR therapy plus chemotherapy in this subgroup of patients. 12 Tumor-infiltrating lymphocytes Since the last decade onward, the immune system has been under investigation as a possible target in the management of different cancer subtypes.

also in 11,005 other papers